磺达肝癸钠注射液与低分子肝素钙注射液在非ST段抬高型急性冠脉综合征患者经皮冠状动脉介入术中有效性和安全性的对比研究

摘要

Objective To compare the effectiveness and safety in non ST-segment elevation acute coronary syndrome patients undergoing PCI between fondaparinux sodium injection and low molecular weight heparins calcium injection.Methods From November 2013 to November 2016,a total of 162 patients with non ST-segment elevation acute coronary syndrome were selected in the Department of Cardiovascular Medicine,the Fourth People's Hospital of Shaanxi Province,and they were divide into control group and study group according to random number table,each of 81 cases.Patients of the two groups received conventional treatment after admission and PCI within 72 hours after admission,meanwhile patients of control group received low molecular weight heparins calcium injection,while patients of study group received fondaparinux sodium injection;both groups continuously treated for 2 months.Incidence of adverse cardiac events during the treatment was observed,TIMI bleeding grade after treatment,PT and APTT before and after treatment were compared between the two groups.Results Incidence of adverse cardiac events of study group was statistically significantly lower than that of control group during the treatment (P ＜ 0.05).TIMI bleeding grade of study group was statistically significantly better than that of control group after treatment (P ＜ 0.05).No statistically significant differences of PT or APTT was found between the two groups before treatment (P ＞ 0.05),while PT and APTT of observation group were statistically significantly shorter than those of control group after treatment (P ＜ 0.05).Conclusion Compared with low molecular weight heparins calcium injection,fondaparinux sodium injection can more effectively reduce the risk of adverse cardiac events and hemorrhage,promote the thrombolysis patients with non ST-segment elevation acute coronary syndrome.%目的 比较磺达肝癸钠注射液与低分子肝素钙注射液在非ST段抬高型急性冠脉综合征(NSTE-ACS)患者经皮冠状动脉介入术(PCI)中的有效性和安全性.方法 选取2013年11月-2016年11月陕西省第四人民医院心血管科收治的NSTE-ACS患者162例,采用随机数字表法分为对照组与研究组,每组81例.两组患者均予以常规治疗并于入院72 h内行PCI,同时对照组患者予以低分子肝素钙注射液治疗,而研究组患者予以磺达肝癸钠注射液治疗;两组患者均连续治疗2个月.观察两组患者治疗期间不良心血管事件发生情况,比较两组患者治疗后TIMI出血分级和治疗前后凝血酶原时间(PT)、活化部分凝血活酶时间(APTT).结果 治疗期间研究组患者不良心血管事件发生率低于对照组(P＜0.05).治疗后研究组患者TIMI出血分级优于对照组(P＜0.05).治疗前两组患者PT、APTT比较,差异无统计学意义(P＞0.05);治疗后研究组患者PT、APTT短于对照组(P＜0.05).结论 与低分子肝素钙注射液相比,磺达肝癸钠注射液可更有效地降低行PCI的NSTE-ACS患者不良心血管事件发生风险和出血风险,促进血栓溶解.